Cargando…

Stable disease, diagnosis and dose are prognostic factors for survival after interleukin-2 immunotherapy

Detalles Bibliográficos
Autores principales:	Kwan, Nathan H, Ockenfels, Brittany A, Patel, Charmi, Miletello, Gerald P, Brantley, Paula R
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2015
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4645469/ http://dx.doi.org/10.1186/2051-1426-3-S2-P138

Ejemplares similares

Stable disease after high dose interleukin-2 (HD IL-2) immunotherapy: observations on long term survival and clinical benefit of additional HD IL-2
por: Kaufman, Howard L, et al.
Publicado: (2014)

Role of dose selection in successful interleukin-2 immunotherapy: solving the Goldilock’s Complex
por: Zloza, Andrew, et al.
Publicado: (2013)

Combination immunotherapy with Interleukin-2 and CTLA-4 blockade decreases tumor growth and improves overall survival
por: Broucek, Joseph R, et al.
Publicado: (2013)

Interleukin-4 receptor targeted immunotherapy of human bladder cancer in animal models
por: Joshi, Bharat H, et al.
Publicado: (2014)

Gene expression profile of CD8 T cells from the responder and non-responder mice following immunotherapy treatment for prostate cancer
por: Dubey, Seema, et al.
Publicado: (2013)

Clinical benefit of high dose IL-2 (HD IL-2) therapy: evidence for improved overall survival in patients with stable disease
por: Hughes, Tasha, et al.
Publicado: (2013)

Thermal dose and radiation dose comparison based on cell survival
por: Lee, Meredith, et al.
Publicado: (2015)

Nivolumab dose selection: challenges, opportunities and lessons learned for cancer immunotherapy
por: Agrawal, Shruti, et al.
Publicado: (2015)

Extent and location of tumor infiltrating lymphocytes in microsatellite stable colon cancer predict outcome to adjuvant active specific immunotherapy
por: Turksma, Annelies, et al.
Publicado: (2015)

High dose interleukin-2 registry, PROCLAIM™; higher center-specific IL-2 dose density correlates with higher response rates
por: Wong, Michael K, et al.
Publicado: (2013)

Complete metastasectomy after high-dose interleukin-2 (HD IL-2) therapy for melanoma
por: Chu, Melinda, et al.
Publicado: (2015)

Generation of interleukin-13 receptor alpha2 antigen expressing modified vaccinia ankara recombinant virus for potential cancer immunotherapy
por: Sato, Yuki, et al.
Publicado: (2014)

Development of an adoptive cell therapy protocol with tumor-infiltrating lymphocytes and intermediate-dose interleukin-2 therapy
por: Nguyen, Linh T, et al.
Publicado: (2013)

Prognostic value of first pass stress perfusion cardiac magnetic resonance in stable coronary artery disease
por: Catalano, Oronzo, et al.
Publicado: (2011)

Activity of dose-dense outpatient intravenous Interleukin-2 preceded by famotidine in metastatic clear cell cancer of the kidney
por: Quan, Walter, et al.
Publicado: (2013)

Targeting cytomegalovirus (CMV) antigens for GBM immunotherapy
por: Nair, Smita K, et al.
Publicado: (2013)

Durability of responses in patients with metastatic renal cell carcinoma treated with high dose interleukin-2 (HD IL-2)
por: Clark, Joseph I, et al.
Publicado: (2015)

Combined depletion of interleukin-1 and interleukin-6 does not exceed single depletion of interleukin -1 in TNF-mediated arthritis
por: Hayer, Silvia, et al.
Publicado: (2012)

Analysis of interleukin-13 receptor alpha2 expression as a prognostic biomarker in surgically resected pancreatic cancer patients
por: Fujisawa, Toshio, et al.
Publicado: (2015)

Interleukin 13 receptor alpha 2 directed immunotherapy targets hepatic fibrosis and tumorigenesis induced by choline deficient diet in an in vivo mouse model of nonalcoholic steatohepatitis
por: Fujisawa, Toshio, et al.
Publicado: (2014)

Impact of annual hospital volume of high dose interleukin-2 infusions on in-patient mortality in patients with melanoma and renal cell carcinoma
por: Mehta, Kathan, et al.
Publicado: (2015)

Efficacy and safety of high-dose interleukin-2 treatment in patients with a history of brain metastases from renal cell carcinoma
por: Chandar, Ashwin, et al.
Publicado: (2015)

Combination immunotherapy with anti-CTLA-4 and interleukin-2 redirects regulatory T cells into tumor-draining lymph nodes and expands anti-tumor CD8+ T cells in the tumor microenvironment
por: Broucek, Joseph, et al.
Publicado: (2014)

Poster 1000: Efficacy and safety of specific sublingual immunotherapy with carbamylated allergoid tablets of ragweed pollen: a dose-ranging study
por: Compalati, Enrico, et al.
Publicado: (2014)

Long-term progression-free survival of patients with metastatic melanoma or renal cell carcinoma following high-dose interleukin-2
por: Clark, Joseph I, et al.
Publicado: (2021)

Differential diagnosis of reactive arthritis in a patient with intravesical BCG immunotherapy
por: Aguridă, Aida Roxana, et al.
Publicado: (2014)

The Nottingham Prognostic Index: 5-year and 10-year survival data for all-cause survival within a screened population
por: Fong, YF, et al.
Publicado: (2012)

Influence of Interleukin-4 and Interleukin-13 on serum immunoglobulin E in house dust mite allergy
por: Panaitescu, Carmen, et al.
Publicado: (2014)

Simultaneous targeting of interleukin-1 and interleukin-18 is required for protection against inflammatory and septic shock
por: Berghe, T Vanden, et al.
Publicado: (2014)

Poxvirus-based active immunotherapy synergizes with immune checkpoint inhibitors to cause tumor regression and extend survival in preclinical models of cancer
por: Foy, Susan P, et al.
Publicado: (2014)

High-dose treatment with ADXS11-001, a listeria monocytogenes (Lm)-listeriolysin O (LLO) immunotherapy, in women with cervical cancer
por: Ghamande, Sharad, et al.
Publicado: (2015)

Betablockers for haemodynamically stable acute myocarditis
por: Monti, Lorenzo, et al.
Publicado: (2014)

Polymorphisms in the interleukin 4, interleukin 13 and corresponding receptor genes are not associated with Systemic Sclerosis and do not influence gene expression
por: Broen, JCA, et al.
Publicado: (2010)

Multi-functional cytotoxic T cell expansion correlates with overall survival after administration of autologous dendritic cell immunotherapy in renal cell cancer patients
por: DeBenedette, M, et al.
Publicado: (2013)

Interleukin-1 antagonists in Mevalonate Kinase Deficiency
por: Galeotti, C, et al.
Publicado: (2011)

Association of mastocytosis with interleukin 31 gene polymorphism
por: Nedoszytko, Boguslaw, et al.
Publicado: (2015)

Our experience of anti-interleukin 1 therapy
por: Gulez, N, et al.
Publicado: (2015)

Immunotherapy generates selective pressure for acquisition of immunogenic neoantigens in escape tumors
por: Pan, Jenny H, et al.
Publicado: (2015)

Stable and robust development of orientation maps and receptive fields
por: Law, Judith S, et al.
Publicado: (2011)

Abdominal sepsis: efficacy of passive immunotherapy
por: Knut, Ruslan, et al.
Publicado: (2007)

Cannot write session to /tmp/vufind_sessions/sess_dlvdi6t5oa2qe9qt17qfjfsib4